

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/129890 A1

(51) International Patent Classification:

C07D 498/04 (2006.01) A61P 35/00 (2006.01)
A61K 31/5365 (2006.01) A61P 17/06 (2006.01)

(21) International Application Number:

PCT/GB2021/053286

(22) International Filing Date:

14 December 2021 (14.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2019667.1 14 December 2020 (14.12.2020) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**
[GB/GB]; Granta Park, Great Abington, Cambridge Cam-
bridgeshire CB21 6DG (GB).

(72) Inventors: **BROWN, Giles Albert**; c/o Heptares Ther-
apeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **CONGREVE,**
Miles Stuart; c/o Heptares Therapeutics Limited, Granta
Park, Great Abington, Cambridge Cambridgeshire CB21
6DG (GB). **TEOBALD, Barry**; c/o Heptares Therapeutics
Limited, Granta Park, Great Abington, Cambridge Cam-
bridgeshire CB21 6DG (GB). **SWAIN, Nigel Alan**; c/o
Heptares Therapeutics Limited, Granta Park, Great Abing-
ton, Cambridge Cambridgeshire CB21 6DG (GB). **FIELD-**
HOUSE, Charlotte; c/o Heptares Therapeutics Limited,
Granta Park, Great Abington, Cambridge Cambridgeshire
CB21 6DG (GB). **PICKWORTH, Mark**; c/o Heptares
Therapeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **BAYRAK-**
DARIAN, Malken; c/o 7171 Frederic Banting, Ville St-
Laurent, Quebec, H4S 1Z9 (CA). **KARILA, Delphine**; c/
o 7171 Frederic Banting, Ville St-Laurent, Quebec, H4S

1Z9 (CA). **BEAUDION, Daniel**; c/o 7171 Frederic Banti-
ng, Ville St-Laurent, Quebec, H4S 1Z9 (CA).

(74) Agent: **STRATAGEM IPM LIMITED**; Meridian Court,
Comberton Road, Toft, Cambridge CB23 2RY (GB).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: H4 ANTAGONIST COMPOUNDS



(1)

(57) Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein Y, Z, R¹, R², R³, R⁴, R⁵ and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.

WO 2022/129890 A1